Los Angeles Capital Management
VKTX icon

Los Angeles Capital Management’s Viking Therapeutics VKTX Stock Holding History

Los Angeles Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Hold
461
– – ﹤0.01% 1816
2026
Q1 		$15K Hold
461
– – ﹤0.01% 1829
2025
Q4 		$17.6K Buy
+461
New +$16.3K ﹤0.01% 1914
2025
Q1 		– Sell
-5,681
Closed -$229K – 1237
2024
Q4 		$229K Sell
5,681
-5,267
-48% -$300K ﹤0.01% 1016
2024
Q3 		$693K Sell
10,948
-1,330
-11% -$78K ﹤0.01% 773
2024
Q2 		$651K Buy
12,278
+372
+3% +$24.4K ﹤0.01% 785
2024
Q1 		$976K Buy
+11,906
New +$530K ﹤0.01% 695

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Los Angeles Capital Management's VKTX Position: Q2 2026 in Review

Los Angeles Capital Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 461 shares worth $18K. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

Los Angeles Capital Management first reported a position in VKTX in Q1 2024 and has held it in 7 quarters since. The position peaked at $976K in Q1 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Los Angeles Capital Management held 461 shares of Viking Therapeutics worth $18K as of Q2 2026.
  • Los Angeles Capital Management left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #1816 holding.
  • Los Angeles Capital Management first reported a position in Viking Therapeutics in Q1 2024 and has held it in 7 quarters since.
  • Los Angeles Capital Management's Viking Therapeutics position peaked at $976K in Q1 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.